EUVIMEDEUVIMED entdecken
Scoping Review

Ramipril vs Candesartan: Scoping Review with ☸️SAIMSARA

SAIMSARA Journal · 02.06.2026 · 1 (1)

DOI: 10.62487/saimsarae1a78e09 ↗

Kurz gefasst

Scoping Review in der Zeitschrift SAIMSARA Journal, online erschienen am 02.06.2026. Die Arbeit nennt 37 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this scoping review is to systematically synthesize and evaluate the comparative efficacy, safety, tolerability, and physiological impacts of ramipril versus candesartan across experimental animal models, laboratory biological systems, and clinical cohorts. The review uses 37 references and builds its evidence map from 33 original studies with 399243 total participants/sample observations (topic-deduplicated ΣN). This scoping review suggests that ramipril and candesartan offer broadly comparable blood-pressure control but diverge meaningfully in tolerability and selected target-organ effects, with candesartan associated with superior exercise blood-pressure reduction in a small crossover study reported across related records, diastolic function improvement, and sustained anti-fibrotic activity, and ramipril showing distinct perioperative bradykinin and fibrinolytic effects during cardiopulmonary bypass. Single-pill combinations of either agent with amlodipine were associated with improved persistence and lower cardiovascular event or mortality risk (HR 0.77 and 0.80) compared with multi-pill regimens. Tolerability signals, including cough and rare bronchial cast formation with ramipril, support individualized switching when class-specific adverse effects emerge. Given the heterogeneous and largely non-pooled evidence base, future head-to-head trials should clarify which patient phenotypes—defined by sex, comorbidity, or exercise exposure—derive the greatest differential benefit from each agent.

Zitieren

APA

(2026). Ramipril vs Candesartan: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal, 1(1). https://doi.org/10.62487/saimsarae1a78e09

Vancouver

Ramipril vs Candesartan: Scoping Review with ☸️SAIMSARA. SAIMSARA Journal. 2026;1(1). doi:10.62487/saimsarae1a78e09

BibTeX
@article{euvimed2026,
  title = {Ramipril vs Candesartan: Scoping Review with ☸️SAIMSARA},
  journal = {SAIMSARA Journal},
  year = {2026},
  volume = {1},
  number = {1},
  doi = {10.62487/saimsarae1a78e09}
}
Kostenlos starten →